Felis ISSN 2398-2950

Capromorelin

Synonym(s): ENTYCE®

Contributor(s): Vetstream Ltd, Marge Chandler

Introduction

Name

  • Capromorelin.

Class of drug

  • Selective ghrelin receptor agonist.

Description

Chemical name

  • 2-amino-N-[2-(3aR-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-1R-benzyloxymethyl-2-oxo-ethyl]-isobutyramide L-tartrate.

Molecular formula

  • C28H35N5O4·C4H6O6

Molecular weight

  • 655.70.

Physical properties

  • Oral solution.

Storage requirements

  • Store at or below 86°F (30°C).

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Inappetence.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed Papers

  • Recent references from VetMed Resource and PubMed.
  • Wofford J A, Zollers B, Rhodes L, Bell M, Heinen E (2018) Evaluation of the safety of daily administration of capromorelin in cats. J Vet Pharmacol Ther 41(2), 324-333 PubMed.
  • Rhodes L, Zollers B, Wofford J A, Heinen E (2017) Capomorelin: a ghrelin receptor agonist and novel therapy for stimulation of appetite in dogs. VetMed Sci 4(1), 3-16 PubMed.
  • Zollers B, Rhodes L & Heinen E (2017) Capromorelin oral solution (ENTYCE®) increases food consumption and body weight when administered for 4 consecutive days to healthy adult Beagle dogs in a randomized, masked, placebo controlled study. BMC Vet Res 13(1), 10 PubMed.
  • Zollers B, Wofford J A, Heinen E, Heuber M, Rhodes L (2016) A Prospective, Randomized, Masked, Placebo-Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite. JVIM  30(6), 1851-1857 PubMed.
  • Zollers B, Huebner M, Armintrout G, Rausch-Derra LC, Rhodes L (2016) Evaluation of the safety in dogs of long-term, daily oral administration of capromorelin (ENTYCE® ), a novel drug for stimulation of appetite. J Vet Pharmacol Ther 40(3), 248-255 PubMed.
  • Zollers B, Rhodes L, Smith RG (2016) Capromorelin increases food consumption, body weight, growth hormone, and sustained insulin-like growth factor 1 concentrations when administered to healthy adult Beagle dogs. J Vet Pharmacol Ther 40(2), 140-147 PubMed.

Other sources of information


ADDED